COMPLETE Commercialization

The Only Complete Commercialization Solution in the Industry

The pharmaceutical pipeline is gaining momentum, led by many first-time launchers. But the reality is companies spend >$200MM over three years leading up to launch, and 66% of drugs still don’t meet launch expectations. This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialization options that effectively maximize their pipelines.

EVERSANA™ COMPLETE Commercialization is an award winning model that disrupted the pharma industry by optimizing investments, minimizing risk and increasing speed to market.

This innovative model:

  • Delivers more value than traditional licensing or launching on your own.
  • Activates a complete, ready-to-deploy, high-performance commercialization and distribution engine.
  • Accelerates your product from early development to marketing, effectively impacting patient outcomes and beyond.
See how others are using this new model effectively by downloading the article Reinventing Launch: The Gold Standard of Drug Commercialization by Greg Skalicky, Chief Revenue Officer.

 

EVERSANA™ COMPLETE Commercialization

Imagine not having to risk building an expensive infrastructure – because we have built a foundation you can customize for your product needs. Activate a complete, ready-to-deploy, high-performance commercialization and distribution engine today!

 

True Financial Benefit

A recent study examined 10 real-world pharma launches and compared them to companies that embraced this new, innovative, scalable commercialization model. The study concluded that those who launched in the traditional model overspent by 23%, without any upside on launch success. Download the white paper to see an in-depth analysis of all launches and costs.

Recent Commercialization Partnerships

GENinCode announces major US commercialisation partnership with EVERSANA

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, is partnering with EVERSANA  to be the launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused on genetic risk. Read the full story.

Resverlogix and EVERSANA Announce Partnership to Support the Launch of Apabetalone for COVID-19 in the United States and Canada

Resverlogix Corp. and EVERSANA announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved. Read the full story.

MedRhythms and EVERSANA announce partnership to launch and commercialize chronic stroke software-based medical device

MedRhythms, a Portland, Maine-based digital therapeutics company that is building direct stimulation, prescription digital therapeutics that use sensors, music and software to improve walking impairments, announced partnership with EVERSANA to launch and commercialize MR-001, its patented software-based medical device designed to treat chronic stroke walking deficits. Read the full story.

Iterum Therapeutics and EVERSANA partner to Support Oral Sulopenem Launch

Iterum Therapeutics, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, it has engaged EVERSANA™, to immediately initiate pre-launch activities, followed by planned commercialization services after the anticipated decision by the FDA in July 2021,. Learn More.

Humanigen and EVERSANA to Launch and Commercialize Lenzilumab for the Treatment of COVID-19

Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, chose EVERSANA  as their partner to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA. Read the full story

“EVERSANA shares our tireless commitment to patients,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “We’ve matched our dedication to research and development in COVID-19 with a proven commercialization partner to ensure lenzilumab will reach patients quickly and efficiently following a potential EUA.”

MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA to commercialize margetuximab in the United States, if approved. Read The Full Story

“We are excited to partner with EVERSANA and leverage their integrated commercial services to efficiently launch margetuximab. We have been working closely with EVERSANA to fully align our commercialization strategies to educate healthcare providers and ensure patient access to margetuximab, while maintaining MacroGenics’ cash runway to fund our broader portfolio.”

Predictable Commercial Success

Complete, full-scale, customizable infrastructure amplified by top industry launch leaders

Engineered to:

  • optimize the launch of precommercial assets
  • capture full revenue potential through maturity

Revolutionary, nontraditional financial deal structures provide flexibility of terms and options

Built to:

  • provide an alternative to traditional and more common strategies, such as selling it, out-licensing or going at it alone
  • reduce up-front cash investments necessary to launch
  • maximize revenue potential and minimize financial risk

Valuable assets demand integrated, predictive and actionable data to maximize growth potential

Empowered to:

  • maximize the ROI of data and analytic investments
  • enhance decision-making
  • create a seamless patient journey and positively impact outcomes

Framework

Powered by our award-winning model, the EVERSANA™ COMPLETE Commercialization framework has six key inflection points that optimize resources and manage costs across commercialization activities.

Contact us to discuss how your asset can immediately benefit from EVERSANA™ COMPLETE Commercialization.